A Phase 4 interventional study of CequaTM (Cyclosporine 0.09%) ophthalmic solution in Dry Eye Disease, sponsored by Sun Pharmaceutical Industries Limited. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-06.
Sponsored by Sun Pharmaceutical Industries Limited · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 7th largest by enrollment of the 41 interventional ones that give a count, is one of 7 that started in 2020, is one of 23 in phase 4, and was the 25th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
The University of New South Wales · Sites in Australia
Ages 18+
Canyon City Eyecare · Sites in United States
Ages 18+
Baylor College of Medicine
Ages 18+
By country, each count listing its studies:
Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 51 across the 41 interventional studies. Of the 35 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 45 have an industry lead sponsor. The 10 most frequent:
Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.
Sun Pharmaceutical Industries Limited has 4 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
5 of the studies testing cyclosporine in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898853The University of New South WalesThe Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes | 2026-12-30 |
| NCT07553455Canyon City EyecareVevye + Flarex Combination Therapy for Dry Eye | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
| NCT07904728Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution | 2027-03-15 |
| NCT07368595Baylor College of MedicineComparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
This is a phase 4, multicenter, open-label, single-arm, 12-week study of subjects with dry eye disease that is inadequately controlled by cyclosporine (CsA) 0.05% ophthalmic emulsion. Subject enrollment will be classified by evidence of dry eye disease (ie, signs, symptoms, or both signs and symptoms). Treatment will be one drop of CsA 0.09% ophthalmic solution (Cequa) in each eye twice daily (BID) for 12 weeks. The study hypothesis is that CsA 0.09% ophthalmic solution will show improved clinical benefit in subjects whose dry eye signs and/or symptoms are inadequately controlled while on CsA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: CequaTM (Cyclosporine 0.09%) ophthalmic solution
One drop CequaTM (Cyclosporine 0.09%) ophthalmic solution in each eye twice daily, approximately 12 hours apart.
Mean Change in Baseline in Total Corneal Fluoroscein Staining Score
Scale for Corneal Staining as defined by the FDA/NEI: 0-4 (0-no staining, 4-severe staining). The higher number indicates more severe. The lower the number indicates less severe staining on the cornea
Time frame: Week12
Change From Baseline in Modified Dry Eye Scoring.
Based on questionnaire asked to subjects (sign and symptoms), modified symptom of dry eye score (range 0 to 100) will be assessed. Increase in score will indicate severity in the symptoms.
Time frame: Week12
Mean Change in Baseline for Conjunctival Staining Assessment
Based on Investigator's judgement, 6 areas of the conjunctiva will be evaluated in a low to moderate intensity. Scale for Conjunctival Staining defined: 0-6 (0 no staining, 6-severe staining). The higher the number indicates more severe. The lower the number indicates less severe staining on the conjunctival
Time frame: Week 12
Changes From Baseline in Central Corneal Staining Score
Five areas of cornea will be evaluated on a 0 to 4 scale and value from 0 (absent) to 4 (severe) to each section will be allotted based on NEI grading scale
Time frame: Week 12
Mean Change in Baseline for Tear Osmolarity Score for Both Eyes
Tear osmolarity of both the eyes will be assessed and score (mOsm/L) will be allotted to each eye. Higher score will indicate severity of the disease (dry eye). Tear osmolarity OU was assessed using the TearLab Osmolarity System Test by collecting nanoliter volumes of tear fluid at each visit from each eyelid margin using the Osmolarity Test Pen and Test Card. Results were interpreted according to the provided instructions and scores (mOsm/L) for each eye were recorded. Normal, mild/moderate, and severe dry eyes had average tear osmolarity values of approximately 302+/-8 mOsm/L, 315+/-10 mOsm/L and 336+/022 mOsm/L, respectively.
Time frame: Week 12
Mean Change From Baseline in Frequency of Artificial Tear Product Use.
Based on entries in the subject diaries, frequency of artificial tear product use will be assessed. Frequency for artificial tear: This is number of times per day recorded in a daily diary log assessed at baseline and week 12. The higher the number the worse the outcome. The lower the number the better the outcome
Time frame: Week 12
Schirmer's Test Score
An unanesthetized Schirmer's test was performed in each eye at least 5 minutes after the lissamine green conjunctival staining to allow for any reflex tearing to subside. At each visit, strips were placed OU at the same time and timed for 5 min. Strips were removed after 5 min and the amount of wetting was recorded in mm and also marked with a line on the strip. The Investigator recorded a score for each eye. A score of greater than 10 mm in 5 minutes is accepted as normal. A score of less than 5 mm in 5 minutes indicates a tear deficiency. A score less than 10 mm in 5 minutes indicates a change from normal in tear production.
Time frame: Week 12
Percentage of Subjects Who Prefer Study Treatments Over Prior Treatment.
Subjects will be asked, which treatment they prefer for the management of the dry eye (prior treatment or study treatment). Note- For this outcome measure, participants were provided the option to not choose either treatment as the preferred treatment.
Time frame: Week 12
| Milestone | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Started | 134 |
| Completed | 115 |
| Not completed | 19 |
Scale for Corneal Staining as defined by the FDA/NEI: 0-4 (0-no staining, 4-severe staining). The higher number indicates more severe. The lower the number indicates less severe staining on the cornea
| score on a scale | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Mean Change in Baseline in Total Corneal Fluoroscein Staining Score | -3.1 ± 2.88 |
Based on questionnaire asked to subjects (sign and symptoms), modified symptom of dry eye score (range 0 to 100) will be assessed. Increase in score will indicate severity in the symptoms.
| score on a scale | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Change From Baseline in Modified Dry Eye Scoring. | -29.14 ± 26.220 |
Based on Investigator's judgement, 6 areas of the conjunctiva will be evaluated in a low to moderate intensity. Scale for Conjunctival Staining defined: 0-6 (0 no staining, 6-severe staining). The higher the number indicates more severe. The lower the number indicates less severe staining on the conjunctival
| score on a scale | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Mean Change in Baseline for Conjunctival Staining Assessment | -2.35 ± 2.918 |
Five areas of cornea will be evaluated on a 0 to 4 scale and value from 0 (absent) to 4 (severe) to each section will be allotted based on NEI grading scale
| score on a scale | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Changes From Baseline in Central Corneal Staining Score | -0.5 ± 0.87 |
Tear osmolarity of both the eyes will be assessed and score (mOsm/L) will be allotted to each eye. Higher score will indicate severity of the disease (dry eye). Tear osmolarity OU was assessed using the TearLab Osmolarity System Test by collecting nanoliter volumes of tear fluid at each visit from each eyelid margin using the Osmolarity Test Pen and Test Card. Results were interpreted according to the provided instructions and scores (mOsm/L) for each eye were recorded. Normal, mild/moderate, and severe dry eyes had average tear osmolarity values of approximately 302+/-8 mOsm/L, 315+/-10 mOsm/L and 336+/022 mOsm/L, respectively.
| mOsm/L | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| OD- Right eye | -4.0 ± 19.44 |
| OS- left eye | -11.7 ± 18.54 |
Based on entries in the subject diaries, frequency of artificial tear product use will be assessed. Frequency for artificial tear: This is number of times per day recorded in a daily diary log assessed at baseline and week 12. The higher the number the worse the outcome. The lower the number the better the outcome
| times product used/day | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Mean Change From Baseline in Frequency of Artificial Tear Product Use. | -1.5 ± 2.39 |
An unanesthetized Schirmer's test was performed in each eye at least 5 minutes after the lissamine green conjunctival staining to allow for any reflex tearing to subside. At each visit, strips were placed OU at the same time and timed for 5 min. Strips were removed after 5 min and the amount of wetting was recorded in mm and also marked with a line on the strip. The Investigator recorded a score for each eye. A score of greater than 10 mm in 5 minutes is accepted as normal. A score of less than 5 mm in 5 minutes indicates a tear deficiency. A score less than 10 mm in 5 minutes indicates a change from normal in tear production.
| mm | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Schirmer's Test Score | 2.4 ± 8.61 |
Subjects will be asked, which treatment they prefer for the management of the dry eye (prior treatment or study treatment). Note- For this outcome measure, participants were provided the option to not choose either treatment as the preferred treatment.
| percentage of participants | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Prefer prior treatment | 21.8 |
| Prefer study treatment | 69.4 |
Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CequaTM (Cyclosporine 0.09%) Ophthalmic Solution | 0/134 (0%) | 0/134 (0%) | 20/134 (14.9%) |
| Event | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Instillation Site IrritationGeneral disorders | 17/134 |
| Instillation Site PainGeneral disorders | 3/134 |
| Age, Continuous(years) | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Mean | 65.5 (23 to 90) |
| Sex: Female, Male(Participants) | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Female | 110 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | CequaTM (Cyclosporine 0.09%) Ophthalmic Solution |
|---|---|
| Hispanic or Latino | 18 |
| Not Hispanic or Latino | 107 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2020 to primary completion in Jun 2022, 23 months.
Results were first posted in Feb 2024, 1 year 7 months after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 23 months is above that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine
Sun Pharmaceutical Industries Limited →